Ixekizumab

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
6 facts to know about the new psoriasis drugFDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.
Ixekizumab superior to etanercept in psoriasis trialsIxekizumab (Eli Lilly) has demonstrated superiority to etanercept (Enbrel, Amgen) in phase 3 studies for the treatment of moderate-to-severe plaque psoriasis.
Pipeline offers promise for psoriasis therapiesDermatologists can expect to see highly effective systemic and oral therapeutic options for psoriasis and psoriatic arthritis added to their toolbox.